2024
GLP1R Gene Expression and Kidney Disease Progression
Triozzi J, Yu Z, Giri A, Chen H, Wilson O, Ferolito B, Ikizler T, Akwo E, Robinson-Cohen C, Gaziano J, Cho K, Phillips L, Tao R, Pereira A, Hung A, Muralidhar S, Moser J, Deen J, Tsao P, Gaziano J, Hauser E, Kilbourne A, Matheny M, Oslin D, Churby L, Whitbourne S, Brewer J, Shayan S, Selva L, Pyarajan S, Cho K, DuVall S, Brophy M, Stephens B, Connor T, Argyres D, Assimes T, Hung A, Kranzler H, Aguayo S, Ahuja S, Alexander K, Androulakis X, Balasubramanian P, Ballas Z, Beckham J, Bhushan S, Boyko E, Cohen D, Dellitalia L, Faulk L, Fayad J, Fujii D, Gappy S, Gesek F, Greco J, Godschalk M, Gress T, Gupta S, Gutierrez S, Harley J, Hamner M, Hurley R, Iruvanti P, Jacono F, Jhala D, Kinlay S, Landry M, Liang P, Liangpunsakul S, Lichy J, Mahan C, Marrache R, Mastorides S, Mattocks K, Meyer P, Moorman J, Morgan T, Murdoch M, Norton J, Okusaga O, Oursler K, Poon S, Rauchman M, Servatius R, Sharma S, Smith R, Sriram P, Strollo P, Tandon N, Villareal G, Walsh J, Wells J, Whittle J, Whooley M, Wilson P, Xu J, Yeh S, Bast E, Dryden G, Hogan D, Joshi S, Lo T, Morales P, Naik E, Ong M, Petrakis I, Rai A, Yen A. GLP1R Gene Expression and Kidney Disease Progression. JAMA Network Open 2024, 7: e2440286. PMID: 39453656, DOI: 10.1001/jamanetworkopen.2024.40286.Peer-Reviewed Original ResearchConceptsGenetic association studiesKidney disease progressionRisk of kidney disease progressionVeterans Affairs Million Veteran ProgramAssociation studiesGenetic risk scoreMillion Veteran ProgramGLP-1RAsDisease progressionIncident end-stage kidney diseaseBody mass indexGlycemic controlGene expressionVeteran ProgramObesity statusMain OutcomesUnadjusted modelsGlucagon-like peptide 1 receptor agonistsStudy participantsPeptide 1 receptor agonistsAbsence of diabetesMass indexMedian follow-upRisk scoreGenotype-Tissue Expression project
2023
Developing Researchers with Expertise in Sex as a Biological Variable through SCORE Career Enhancement Core Center Programs
Zakiniaeiz Y, Peltier M, Mineur Y, Gueorguieva R, Picciotto M, Petrakis I, Cosgrove K, McKee S. Developing Researchers with Expertise in Sex as a Biological Variable through SCORE Career Enhancement Core Center Programs. Journal Of Women's Health 2023, 32: 852-857. PMID: 37585509, PMCID: PMC10457604, DOI: 10.1089/jwh.2023.0015.Peer-Reviewed Original Research
2010
Analgesic Effects of Ethanol Are Influenced by Family History of Alcoholism and Neuroticism
Ralevski E, Perrino A, Acampora G, Koretski J, Limoncelli D, Petrakis I. Analgesic Effects of Ethanol Are Influenced by Family History of Alcoholism and Neuroticism. Alcohol Clinical And Experimental Research 2010, 34: 1433-1441. PMID: 20497133, PMCID: PMC9136640, DOI: 10.1111/j.1530-0277.2010.01228.x.Peer-Reviewed Original ResearchConceptsFamily historyAnalgesic responseHigh N scoresAnalgesic effectNoxious electrical stimulationPositive family historyStart of infusionDoses of ethanolSeparate test daysNegative family historyTest dayExperience of painN scoreMore analgesiaPlacebo dayPain assessmentPersonality traitsIntravenous administrationHealthy subjectsEthanol challengeLow doseElectrical stimulationAlcoholismThirty-oneLow N scoresSPECT imaging of nicotinic acetylcholine receptors in nonsmoking heavy alcohol drinking individuals
Esterlis I, Cosgrove KP, Petrakis IL, McKee SA, Bois F, Krantzler E, Stiklus SM, Perry EB, Tamagnan GD, Seibyl JP, Krystal JH, Staley JK. SPECT imaging of nicotinic acetylcholine receptors in nonsmoking heavy alcohol drinking individuals. Drug And Alcohol Dependence 2010, 108: 146-150. PMID: 20074869, PMCID: PMC2871672, DOI: 10.1016/j.drugalcdep.2009.12.006.Peer-Reviewed Original ResearchConceptsDrinks/occasionNicotinic acetylcholine receptorsControl nonsmokersAcetylcholine receptorsHeavy drinkersHeavy drinkingLast alcoholic beverageHeavy alcohol drinkersHeavy alcoholSingle photon emissionSeverity of drinkingEffect of ageTobacco smokingAlcohol drinkersAlcohol drinkingCommon neural substrateNonsmokersAlcohol consumptionReceptor availabilityLarger studyAlcohol drinksAlcohol use behaviorsAddictive disordersDrinkersNeural substrates
2009
Varenicline Reduces Alcohol Self-Administration in Heavy-Drinking Smokers
McKee SA, Harrison EL, O'Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM, Picciotto MR, Petrakis IL, Estevez N, Balchunas E. Varenicline Reduces Alcohol Self-Administration in Heavy-Drinking Smokers. Biological Psychiatry 2009, 66: 185-190. PMID: 19249750, PMCID: PMC2863311, DOI: 10.1016/j.biopsych.2009.01.029.Peer-Reviewed Original ResearchConceptsHeavy drinking smokersSelf-administration periodAlcohol consumptionPartial nicotinic agonistPlacebo-controlled investigationEffects of vareniclineReduced ethanol intakeAlcohol Self-AdministrationAlcohol use disorderNicotinic acetylcholine receptorsMedication pretreatmentAdverse eventsNumber of drinksPreclinical evidenceAdditional drinkEthanol intakeTobacco dependenceDaily smokersPriming doseVareniclineComorbid disordersNicotinic agonistsUse disordersPriming drinkPotential treatment
2008
Ethanol-like effects of thiopental and ketamine in healthy humans
Dickerson D, Pittman B, Ralevski E, Perrino A, Limoncelli D, Edgecombe J, Acampora G, Krystal J, Petrakis I. Ethanol-like effects of thiopental and ketamine in healthy humans. Journal Of Psychopharmacology 2008, 24: 203-211. PMID: 19028835, PMCID: PMC4484757, DOI: 10.1177/0269881108098612.Peer-Reviewed Original ResearchConceptsEthanol-like effectsEthanol-related effectsNMDA receptor antagonistBlock NMDA receptorsNMDA receptor antagonismSeparate test daysGamma-aminobutyric acidReceptor antagonismSubanesthetic dosesReceptor antagonistNMDA receptorsFamily historyEthanol intoxicationHealthy humansPharmacological agentsEthanol effectsKetamineReceptor activityReceptor functionLarger studyBehavioral effectsThiopentalIntoxicationSubjective intoxicationTest dayModulation of the cortical processing of novel and target stimuli by drugs affecting glutamate and GABA neurotransmission
Watson TD, Petrakis IL, Edgecombe J, Perrino A, Krystal JH, Mathalon DH. Modulation of the cortical processing of novel and target stimuli by drugs affecting glutamate and GABA neurotransmission. The International Journal Of Neuropsychopharmacology 2008, 12: 357-370. PMID: 18771605, PMCID: PMC2900256, DOI: 10.1017/s1461145708009334.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalysis of VarianceCerebral CortexDouble-Blind MethodElectroencephalographyEvoked PotentialsFemaleGABA ModulatorsHumansKetamineMalePain MeasurementPattern Recognition, VisualPhotic StimulationReaction TimeReceptors, GABA-BReceptors, N-Methyl-D-AspartateStatistics as TopicThiopentalYoung AdultConceptsPlacebo-controlled studyNMDA receptor systemSubanaesthetic dosesGABA neurotransmissionChallenge sessionsDrug effectsNMDA antagonismHealthy adultsNovel stimuliCortical processingReceptor systemPlaceboDrugsCounterbalanced orderKetaminePotential correlatesNeural correlatesP3a amplitudeNovelty processingP300 componentStandard stimuliStimulus processingStimuliTarget stimuliN2 amplitude
2001
Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers
Oliveto A, McCance-Katz F, Singha A, Petrakis I, Hameedi F, Kosten T. Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers. Drug And Alcohol Dependence 2001, 63: 155-167. PMID: 11376920, DOI: 10.1016/s0376-8716(00)00198-8.Peer-Reviewed Original ResearchContingency Management Interventions: From Research to Practice
Petry N, Petrakis I, Trevisan L, Wiredu G, Boutros N, Martin B, Kosten T. Contingency Management Interventions: From Research to Practice. American Journal Of Psychiatry 2001, 158: 694-702. PMID: 11329388, DOI: 10.1176/appi.ajp.158.5.694.Peer-Reviewed Original Research
2000
Cocaine use and the mid-latency auditory evoked responses
Boutros N, Campbell D, Petrakis I, Krystal J, Caporale M, Kosten T. Cocaine use and the mid-latency auditory evoked responses. Psychiatry Research 2000, 96: 117-126. PMID: 11063784, DOI: 10.1016/s0165-1781(00)00207-9.Peer-Reviewed Original ResearchConceptsCocaine-dependent subjectsInter-stimulus intervalMid-latency auditoryAge-matched healthy control subjectsCocaine useHealthy control subjectsDifferent inter-stimulus intervalsChronic cocaine useLong inter-stimulus intervalsPaired-click paradigmControl subjectsP50 componentN100 componentSignificant decreaseSubjectsAuditoryResponse paradigmSex Differences in Self-Reported and Physiological Response to Oral Cocaine and Placebo in Humans
Singha A, McCance-Katz E, Petrakis I, Kosten T, Oliveto A. Sex Differences in Self-Reported and Physiological Response to Oral Cocaine and Placebo in Humans. The American Journal Of Drug And Alcohol Abuse 2000, 26: 643-657. PMID: 11097197, DOI: 10.1081/ada-100101900.Peer-Reviewed Original ResearchConceptsBad drug effectsSex differencesSystolic blood pressureCocaine-abusing volunteersGreater increasePentobarbital-ChlorpromazineBlood pressurePlacebo controlDrug effectsActive drugOral cocainePlaceboBaseline ratingsCocaineGreater ratingsMalesDrugsFemalesPhysiological responsesResponseAlcohol groupDifferencesVolunteers
1999
CSF Monoamine Metabolite and Beta Endorphin Levels in Recently Detoxified Alcoholics and Healthy Controls: Prediction of Alcohol Cue‐Induced Craving?
Petrakis I, Trevisan L, D'Souza C, Gil R, Krasnicki S, Webb E, Heninger G, Cooney N, Krystal J. CSF Monoamine Metabolite and Beta Endorphin Levels in Recently Detoxified Alcoholics and Healthy Controls: Prediction of Alcohol Cue‐Induced Craving? Alcohol Clinical And Experimental Research 1999, 23: 1336-1341. PMID: 10470976, DOI: 10.1111/j.1530-0277.1999.tb04355.x.Peer-Reviewed Original ResearchConceptsAlcohol-dependent patientsHealthy controlsEndorphin levelsCSF levelsMonoamine metabolitesCSF measuresHealthy subjectsNorepinephrine metabolite MHPGLower CSF levelsBeta-endorphin levelsEarly-onset patientsCerebrospinal fluid levelsLate-onset patientsCentral neurotransmitter systemsCSF monoamine metabolitesDopamine metabolite HVAAlcohol cue exposureAlcohol-dependent individualsCue-Induced CravingAlcohol cue reactivityLumbar punctureMetabolite HVANeurotransmitter systemsMonoaminergic dysregulationMetabolite MHPG
1998
Naltrexone Augmentation of Neuroleptics in Schizophrenia
Sernyak M, Glazer W, Heninger G, Charney D, Woods S, Petrakis I, Krystal J, Price L. Naltrexone Augmentation of Neuroleptics in Schizophrenia. Journal Of Clinical Psychopharmacology 1998, 18: 248-251.. PMID: 9617985, DOI: 10.1097/00004714-199806000-00011.Peer-Reviewed Original ResearchConceptsBrief Psychiatric Rating ScaleTotal BPRS scoreBPRS scoresNegative symptomsAddition of naltrexoneBPRS subscale scoresOngoing neuroleptic treatmentSingle-blind basisPlacebo-controlled trialSingle-blind fashionSubscale scoresBPRS total scorePsychiatric Rating ScaleDSM-III criteriaSubsequent treatmentRepeated-measures analysisNaltrexone augmentationNeuroleptic medicinesNeuroleptic regimenTransient exacerbationPlacebo armNeuroleptic treatmentClinical benefitRepeated-measures ANOVANaltrexoneFluoxetine treatment of depressive disorders in methadone-maintained opioid addicts
Petrakis I, Carroll K, Nich C, Gordon L, Kosten T, Rounsaville B. Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug And Alcohol Dependence 1998, 50: 221-226. PMID: 9649975, DOI: 10.1016/s0376-8716(98)00032-5.Peer-Reviewed Original ResearchConceptsCocaine useOpioid addictsMedication effectsDepressive symptomsSignificant decreaseEffectiveness of fluoxetineSelf-reported cocaine useDrug use outcomesSubsample of subjectsFluoxetine treatmentUrine toxicologySelf-reported useDepressive disorderSevere depressionHeroin useFluoxetineEffective agentUse outcomesDepressionPlaceboSignificant differencesTreatmentSymptomsAddictsMethadone
1997
Effect of alpha-methyl-para-tyrosine on response to cocaine challenge
Stine S, Krystal J, Petrakis I, Jatlow P, Heninger G, Kosten T, Chamey D. Effect of alpha-methyl-para-tyrosine on response to cocaine challenge. Biological Psychiatry 1997, 42: 181-190. PMID: 9232210, DOI: 10.1016/s0006-3223(96)00331-9.Peer-Reviewed Original ResearchConceptsDopamine metabolite homovanillic acidCocaine-induced euphoriaNorepinephrine metabolite 3Placebo-controlled studyBlood pressure responseMetabolite homovanillic acidReduced plasma levelsTyrosine hydroxylase inhibitorSerum cocaine levelsTuberoinfundibular dopamine systemAMPT pretreatmentAcute reductionIntranasal administrationPara-tyrosinePlasma levelsProlactin levelsCocaine challengeHomovanillic acidCatecholamine synthesisHeart rateHydroxylase inhibitorAlpha-methylDopamine systemCocaine levelsTherapeutic potential
1995
Fluoxetine Treatment for Dually Diagnosed Methadone Maintained Opioid Addicts:
Petrakis I, Carroll K, Gordon L, Cushing G, Rounsaville B. Fluoxetine Treatment for Dually Diagnosed Methadone Maintained Opioid Addicts:. Journal Of Addictive Diseases 1995, 13: 25-32. PMID: 7734457, DOI: 10.1300/j069v13n03_03.Peer-Reviewed Original Research
1992
Adjunctive desipramine in the treatment of cocaine abusing schizophrenics.
Ziedonis D, Richardson T, Lee E, Petrakis I, Kosten T. Adjunctive desipramine in the treatment of cocaine abusing schizophrenics. Psychopharmacology Bulletin 1992, 28: 309-14. PMID: 1480735.Peer-Reviewed Original ResearchConceptsAntipsychotic agentsSchizophrenic patientsOpen-label outpatient studySubstance abuse relapse preventionTreatment programDual diagnosis treatment programOnly antipsychotic agentTreatment of cocaineCocaine-positive urinesLifetime prevalence ratesRelapse prevention programAdjunctive pharmacotherapyOutpatient studyPrevalence ratesPsychiatric symptomsPatientsCocaine abuseRelapse preventionPrevention programsCocaine usageDMI groupPharmacotherapyDesipramineSymptomsAgents
1991
Bupropion Reduces Cocaine Abuse in Methadone-Maintained Patients
Margolin A, Kosten T, Petrakis I, Avants S, Kosten T. Bupropion Reduces Cocaine Abuse in Methadone-Maintained Patients. JAMA Psychiatry 1991, 48: 87-87. PMID: 1898631, DOI: 10.1001/archpsyc.1991.01810250089015.Peer-Reviewed Original Research
1984
Contrast discrimination in the cat
Blake R, Petrakis I. Contrast discrimination in the cat. Behavioural Brain Research 1984, 12: 155-162. PMID: 6466435, DOI: 10.1016/0166-4328(84)90038-x.Peer-Reviewed Original Research